menu
    • menu

    Company profile for GondolaBio

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    GondolaBio is a clinical-stage biopharmaceutical company developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, it secured $300M in private financing in 2024, becoming an independent entity within the BridgeBio ecosystem. Focused on high unmet needs in neurology, pulmonology, cardiology, nephrology, and endocrinology, GondolaBio leverages cutting-edge research to create breakthrough me...
    GondolaBio is a clinical-stage biopharmaceutical company developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, it secured $300M in private financing in 2024, becoming an independent entity within the BridgeBio ecosystem. Focused on high unmet needs in neurology, pulmonology, cardiology, nephrology, and endocrinology, GondolaBio leverages cutting-edge research to create breakthrough medicines. Based on the Stanford Life Sciences campus, it fosters collaboration between top scientists, industry leaders, and academic innovators to drive medical advancements.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GondolaBioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3160 Porter Drive #250, Palo Alto, CA, 94304
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://gondolabio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/gondolabio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gondolabio Gets FDA Orphan Drug, Fast Track For PORT-77
    Gondolabio Gets FDA Orphan Drug, Fast Track For PORT-77

    21 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251014131763/en/GondolaBio-Receives-U.S.-FDA-Orphan-Drug-and-Fast-Track-Designations-for-PORT-77-for-the-Treatment-of-Erythropoietic-Protoporphyria-EPP-and-X-Linked-Protoporphyria-XLP

    BUSINESSWIRE
    21 Oct 2025
    Share Share
    GondolaBio & n-Lorem Partner on ASO Therapies for Genetic Disease
    GondolaBio & n-Lorem Partner on ASO Therapies for Genetic Disease

    17 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241217534463/en/GondolaBio-and-n-Lorem-Foundation-Partner-to-Advance-Novel-ASO-Therapies-for-Genetic-Diseases

    BUSINESSWIRE
    17 Dec 2024
    Share Share
    BridgeBio Launches GondolaBio With $300M, Transfers Programs
    BridgeBio Launches GondolaBio With $300M, Transfers Programs

    22 Aug 2024

    // BIOSPACE

    https://www.biospace.com/business/bridgebio-launches-gondolabio-with-300m-transfers-programs-to-joint-venture

    BIOSPACE
    22 Aug 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search